Secreted galectin-3 as a possible biomarker for the immunomodulatory potential of human umbilical cord mesenchymal stromal cells

Cytotherapy

Volumn 15, Issue 10, 2013, Pages 1208-1217

  Liu, Guang Yang ^a,b   Xu, Yi ^b   Li, Yan ^b   Wang, Li Hua ^c   Liu, Yong Jun ^b   Zhu, Delin ^b  

^a TIANJIN UNIVERSITY   (China)

^b Alliancells Institute of Stem Cells and Translational Regenerative Medicine   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Biomarker; Galectin 3; Immunomodulatory; Umbilical cord derived mesenchymal stromal cells

Indexed keywords

GALECTIN 3; HLA G ANTIGEN; INTERLEUKIN 10; KYNURENINE; MESSENGER RNA; PROSTAGLANDIN E2; SCATTER FACTOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CELL SURFACE; COCULTURE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MESENCHYMAL STROMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; UMBILICAL CORD; WESTERN BLOTTING;

BIOMARKER; GALECTIN-3; IMMUNOMODULATORY; UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELLS;

BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; GALECTIN 3; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STROMAL CELLS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; UMBILICAL CORD;

EID: 84883229944     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.05.011     Document Type: Article

References (46)

1. Friedenstein A.J., Chailakhyan R.K., Gerasimov U.V. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987, 20:263-272.
2. Vodyanik M.A., Yu J., Zhang X., Tian S., Stewart R., Thomson J.A., et al. Amesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 2010, 7:718-729.
3. Choi Y.S., Jeong J.A., Lim D.S. Mesenchymal stem cell-mediated immature dendritic cells induce regulatory T cell-based immunosuppressive effect. Immunol Invest 2012, 41:214-229.
4. Li F.R., Wang X.G., Deng C.Y., Qi H., Ren L.L., Zhou H.X. Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clin Exp Immunol 2010, 161:357-363.
5. Abdelrazik H., Spaggiari G.M., Chiossone L., Moretta L. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 2011, 41:3281-3290.
6. Tomchuck S.L., Zwezdaryk K.J., Coffelt S.B., Waterman R.S., Danka E.S., Scandurro A.B. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008, 26:99-107.
7. Sato K., Ozaki K., Oh I., Meguro A., Hatanaka K., Nagai T., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
8. Zhou K., Zhang H., Jin O., Feng X., Yao G., Hou Y., et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008, 5:417-424.
9. Kebriaei P., Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011, 13:262-268.
10. Simpson D.L., Boyd N.L., Kaushal S., Stice S.L., Dudley S.C. Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair. Biotechnol Bioeng 2012, 109:274-283.
11. Ra J.C., Kang S.K., Shin I.S., Park H.G., Joo S.A., Kim J.G., et al. Stem cell treatment for patients with autoimmune disease bysystemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. JTransl Med 2011, 9:181.
12. Ogawa Y., Shimmura S., Kawakita T., Yoshida S., Kawakami Y., Tsubota K. Epithelial mesenchymal transition in human ocular chronic graft-versus-host disease. Am J Pathol 2009, 175:2372-2381.
13. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011, 10:649-656.
14. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
15. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
16. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
17. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
18. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymalstem cells is required to suppress Tlymphocyte andnatural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
19. Nasef A., Mathieu N., Chapel A., Frick J., Francois S., Mazurier C., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237.
20. Zeddou M., Briquet A., Relic B., Josse C., Malaise M.G., Gothot A., et al. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biol Int 2010, 34:693-701.
21. Banas A., Teratani T., Yamamoto Y., Tokuhara M., Takeshita F., Quinn G., et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007, 46:219-228.
22. Jin J.D., Wang H.X., Xiao F.J., Wang J.S., Lou X., Hu L.D., et al. Anovel rich source of human mesenchymal stem cells from the debris of bone marrow samples. Biochem Biophys Res Commun 2008, 376:191-195.
23. Lu L.L., Liu Y.J., Yang S.G., Zhao Q.J., Wang X., Gong W., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006, 91:1017-1026.
24. Cho P.S., Messina D.J., Hirsh E.L., Chi N., Goldman S.N., Lo D.P., et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2008, 111:430-438.
25. Aldinucci A., Rizzetto L., Pieri L., Nosi D., Romagnoli P., Biagioli T., et al. Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. JImmunol 2010, 185:5102-5110.
26. Prasanna S.J., Gopalakrishnan D., Shankar S.R., Vasandan A.B. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010, 5:e9016.
27. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. JImmunol 2003, 171:3426-3434.
28. Rabinovich G.A., Toscano M.A. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009, 9:338-352.
29. Thijssen V.L., Poirier F., Baum L.G., Griffioen A.W. Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 2007, 110:2819-2827.
30. Sioud M., Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol 2007, 37:2834-2846.
31. Sioud M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol 2011, 73:79-84.
32. Sioud M., Mobergslien A., Boudabous A., Floisand Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol 2010, 71:267-274.
33. Sioud M., Mobergslien A., Boudabous A., Floisand Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol 2011, 38:385-390.
34. Gieseke F., Bohringer J., Bussolari R., Dominici M., Handgretinger R., Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116:3770-3779.
35. Stowell S.R., Qian Y., Karmakar S., Koyama N.S., Dias-Baruffi M., Leffler H., et al. Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. JImmunol 2008, 180:3091-3102.
36. Leijs M.J., van Buul G.M., Lubberts E., Bos P.K., Verhaar J.A., Hoogduijn M.J., et al. Effect of arthritic synovial fluids on the expression of immunomodulatory factors by mesenchymal stem cells: an explorative in vitro study. Front Immunol 2012, 3:231.
37. Wu K.H., Chan C.K., Tsai C., Chang Y.H., Sieber M., Chiu T.H., et al. Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation 2011, 91:1412-1416.
38. Sun L., Wang D., Liang J., Zhang H., Feng X., Wang H., et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010, 62:2467-2475.
39. Liu Y., Mu R., Wang S., Long L., Liu X., Li R., et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010, 12:R210.
40. Radosavljevic G., Volarevic V., Jovanovic I., Milovanovic M., Pejnovic N., Arsenijevic N., et al. The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res 2012, 52:100-110.
41. Ahmad N., Gabius H.J., Andre S., Kaltner H., Sabesan S., Roy R., et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. JBiol Chem 2004, 279:10841-10847.
42. Dumic J., Dabelic S., Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760:616-635.
43. Demetriou M., Granovsky M., Quaggin S., Dennis J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001, 409:733-739.
44. Ryan J.M., Barry F., Murphy J.M., Mahon B.P. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007, 149:353-363.
45. Chen K., Wang D., Du W.T., Han Z.B., Ren H., Chi Y., et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol 2010, 135:448-458.
46. English K., Ryan J.M., Tobin L., Murphy M.J., Barry F.P., Mahon B.P. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009, 156:149-160.